CCCecília Beatriz Bittencourt Viana Cruz

Cecília Beatriz Bittencourt Viana Cruz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecília Beatriz Bittencourt Viana Cruz has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy

    by Stephanie Itala Rizk, Isabela Bispo Santos da Silva Costa, Cecília Beatriz Bittencourt Viana Cruz, Brunna Pileggi, Fernanda Thereza de Almeida Andrade, Thalita Barbosa Gonzalez, Cristina Salvadori Bittar, Julia Tizue Fukushima, Vinicius Caldeira Quintao, Eduardo Atsushi Osawa, et al.

    Background: Cancer therapy–related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces heart rate without affecting contractility and showed anti‐inflammatory, antioxidant, and antiapoptotic effects in experimental cardiotoxicity models. This study aims to evaluate the effect of ivabradine on cancer therapy–related cardiac dysfunction in patients with lymphoma or sarcoma treated with anthracycline. Methods: In a randomized, triple‐blind trial, patients starting anthracycline therapy received either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was the incidence of cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months from baseline. Secondary outcomes included 12‐month clinical outcomes, a ≥10% decrease in the left ventricular ejection fraction to 2 (250–300 mg/m 2 ) in both groups. Cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months was reached in 57% versus 50% in the ivabradine and placebo groups (odds ratio, 1.32 [95% CI, 0.61–2.83]; P =0.477). Fewer patients in the ivabradine group than in the placebo group had troponin T levels ≥14 ng/L (16 [39.0%] versus 23 [62.2%]; P =0.041) at 6 months, with this difference not maintained at the 12‐month follow‐up. In addition, there were no differences in the other secondary outcomes. Conclusions: A fixed 10 mg/day dose of ivabradine does not protect patients with cancer against anthracycline cardiotoxicity. Registration: URL: https://clinicaltrials.gov/ ; Unique Identifier: NCT03650205.


  • Open Access

    Interpretação Equivocada da Função Diastólica Indeterminada: Conhecimento e Percepções a Partir de uma Pesquisa Entre Cardiologistas Brasileiros

    by Daniela Do Carmo Rassi, Salvador Rassi, Jorge Eduardo Assef, Alex dos Santos Felix, Adenalva Lima de Souza Beck, Cecília Beatriz Bittencourt Viana Cruz, Silvio Henrique Barberato

    Fundamento: A disfunção diastólica (DD) é altamente prevalente e está associada a alta taxa de morbidade e mortalidade. Diretrizes mais recentes introduziram a classificação de Função ou Disfunção Diastólica Indeterminada (FDI ou DDI), mas ambos os diagnósticos ainda são pouco compreendidos na prática clínica, com prevalência variável. Objetivos: Avaliar o entendimento sobre FDI e DDI entre cardiologistas não ecocardiografistas no Brasil. Métodos: Pesquisa online de abrangência nacional distribuída por plataformas de mensagens móveis, com um questionário breve e anônimo sobre conhecimento e interpretação da Função Diastólica. Resultados: Um total de 570 cardiologistas de todas as regiões do Brasil participaram do estudo. A maioria dos participantes (64,21%) possuía mais de dez anos de experiência clínica. Enquanto 71% identificaram corretamente os graus 2 ou 3 como indicativos de pressões de enchimento elevadas, apenas 34,21% compreendiam com precisão os critérios diagnósticos para FDI ou DDI. Entre os equívocos associados à classificação indeterminada, destacam-se atribuição desse status a condições que interferem na avaliação da diástole (49,12%), limitações técnicas dos equipamentos de ecocardiografia (3,33%) e suposta falta de conhecimento dos ecocardiografistas (4,91%). Além disso, 46,7% relataram encontrar esse diagnóstico raramente nos laudos, 33,5% acreditavam que essa classificação influenciava a conduta clínica e 43,5% consideravam que o exame poderia ter sido melhor realizado. Conclusão: Apesar do conhecimento sobre a função diastólica, a interpretação equivocada de FDI ou DDI ainda é comum entre cardiologistas não ecocardiografistas. Investimentos em educação, com compartilhamento desses conceitos aos clínicos, e diretrizes claras são essenciais para otimizar o uso e a precisão diagnóstica na ecocardiografia.

  • Misinterpretation of Indeterminate Diastolic Function: Awareness and Insights from a Survey among Brazilian Cardiologists

    by Daniela Do Carmo Rassi, Salvador Rassi, Jorge Eduardo Assef, Alex dos Santos Felix, Adenalva Lima de Souza Beck, Cecília Beatriz Bittencourt Viana Cruz, Silvio Henrique Barberato


  • Open Access

    Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia sobre o Uso do Strain Miocárdico na Rotina do Cardiologista – 2023

    by André Luiz Cerqueira Almeida, Marcelo Dantas Tavares de Melo, David Costa de Souza Le Bihan, Marcelo Luiz Campos Vieira, José Luiz Barros Pena, José Maria Del Castillo, Henry Abensur, Renato de Aguiar Hortegal, Maria Estefania Bosco Otto, Rafael Bonafim Piveta, et al.

    Sumário 1. Conceitos Básicos sobre o Estudo da Deformação do Ventrículo Esquerdo 7 1.1. Breve Introdução aos Princípios Físicos da Formação dos Speckles na Imagem Cardiovascular 7 […] Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia sobre o Uso do Strain Miocárdico na Rotina do Cardiologista – 2023 Sumário 1. Conceitos Básicos sobre o Estudo da Deformação do Ventrículo Esquerdo 7 1.1. Breve Introdução aos Princípios Físicos da Formação dos Speckles na Imagem Cardiovascular 7 […] Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia sobre o Uso do Strain Miocárdico na Rotina do Cardiologista – 2023


  • Global Longitudinal Strain as Predictor of Chemotherapy-Induced Cardiotoxicity

    by Instituto do Coração (InCor) do Hospital das Clínicas, Monica Samuel Avila, Marco Stephan Lofrano Alves, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley Junior, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Ludhmila Abrahão Hajjar, Instituto Do Câncer Do Estado de São Paulo-Usp, Roberto Kalil Filho, et al.

    Fundamento: A cardiotoxicidade induzida por quimioterapia (CiC) é uma complicação importante entre os pacientes que recebem antraciclinas. Biomarcadores e parâmetros de imagem têm sido estudados por sua capacidade de identificar pacientes com risco de desenvolver essa complicação. O strain longitudinal global do ventrículo esquerdo (SLG-VE) tem sido descrito como um parâmetro sensível para detectar disfunção sistólica, mesmo na presença de fração de ejeção do ventrículo esquerdo (FEVE) preservada. Objetivo: avaliar o papel do SLG-VE como preditor de CiC. Métodos: O presente estudo consiste em uma análise post-hoc do estudo CECCY (Carvedilol for Prevention of ChemotherapyRelated Cardiotoxicity [Carvedilol para Prevenção da Cardiotoxicidade Relacionada à Quimioterapia]), que avaliou a prevenção primária de cardiotoxicidade com carvedilol durante quimioterapia com doxorrubicina em uma população com câncer de mama. Definiu-se cardiotoxicidade como uma redução >10% na FEVE. O SLG-VE foi obtido antes da quimioterapia em pacientes sem doença cardiovascular prévia ou anormalidades no ecocardiograma. Resultados: Trinta e um pacientes submetidos a estudo ecocardiográfico completo incluindo avaliação de SLG-VE antes da quimioterapia foram incluídos nesta análise. Um SLG-VE absoluto <16,9% antes da quimioterapia mostrou 100% de sensibilidade e 73% de especificidade para predizer cardiotoxicidade (AUC=0,85; IC 95% 0,680–0,959, p<0,001). Nesta população, os valores de FEVE antes da quimioterapia não foram preditores de CiC (IC 95% 0,478 a -0,842, p=0,17). A associação de baixos níveis séricos de SLG-VE (17 pg/mL) dois meses após a quimioterapia aumentou a precisão para detectar CiC de início precoce (100% de sensibilidade, 88% de especificidade, AUC=0,94; IC 95% 0,7810,995, p<0,0001). Conclusões: Nossos dados sugerem que o SLG-VE é um possível preditor de cardiotoxicidade induzida por quimioterapia. São necessários estudos maiores para confirmar a relevância clínica desse parâmetro ecocardiográfico nesse cenário clínico.

  • Global Longitudinal Strain as Predictor of Chemotherapy-Induced Cardiotoxicity

    by Monica Samuel Avila, Marco Stephan Lofrano Alves, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley Junior, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Ludhmila Abrahão Hajjar, Cancer Institute do Estado de São Paulo (USP), Roberto Kalil Filho, Cecilia Beatriz Bittencourt Viana Cruz, et al.

    Background: Chemotherapy-induced cardiotoxicity (ChC) is an important complication among patients receiving anthracyclines. Biomarkers and imaging parameters have been studied for their ability to identify patients at risk of developing ChC. Left ventricular global longitudinal strain (LV-GLS) is a sensitive parameter for detecting systolic dysfunction despite the presence of preserved left ventricular ejection fraction (LVEF). Objective: To evaluate the role of the LV-GLS as a predictor of ChC. Methods: This was a post-hoc analysis of the Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity trial, which evaluated the primary prevention of cardiotoxicity with carvedilol during doxorubicin chemotherapy in a population of patients with breast cancer. Cardiotoxicity was defined as a reduction ≥10% in LVEF. LV-GLS was determined before chemotherapy in patients with no prior cardiovascular disease or echocardiogram abnormalities. Results: Thirty-one patients for whom a complete echocardiography study including measurement of LV-GLS was performed before chemotherapy were included in this analysis. An absolute LV-GLS<16.9% before chemotherapy showed 100% sensitivity and 73% specificity for predicting cardiotoxicity (area under the curve [AUC], 0.85; 95% confidence interval [CI], 0.680–0.959; p<0.001). In this population, LVEF values before chemotherapy did not predict ChC (95% CI, 0.478 to -0.842; p=0.17). The association of low LV-GLS (17 pg/mL) at 2 months after chemotherapy increased the accuracy for detecting early-onset ChC (100% sensitivity, 88% specificity; AUC, 0.94; 95% CI, 0.781–0.995; p<0.0001). Conclusions: Our data suggest that LV-GLS is a potential predictor of ChC. Larger studies are needed to confirm its clinical relevance in this clinical setting.

  • Open Access

    Usefulness of Speckle Tracking Echocardiography and Biomarkers for Detecting Acute Cellular Rejection After Heart Transplantation

    by Cecília Beatriz Bittencourt Viana Cruz, Ludhmila A. Hajjar, Fernando Bacal, Marco S. Lofrano-Alves, Márcio S.M. Lima, Maria C. Abduch, Marcelo L.C. Viera, Hsu P. Chiang, Juliana B. C. Salviano, Isabela Bispo Costa, et al.

    Background: Acute cellular rejection (ACR) is a major complication after heart transplantation. Endomyocardial biopsy (EMB) remains the gold standard for its diagnosis, but it has concerning complications. We evaluated the usefulness of speckle tracking echocardiography (STE) and biomarkers for detecting ACR after heart transplantation.Methods: We prospectively studied 60 transplant patients with normal left and right ventricular systolic function who underwent EMB for surveillance six months after transplantation. Sixty age- and sex-matched healthy individuals constituted the control group. Conventional echocardiographic parameters, left ventricular global longitudinal, radial and circumferential strain (LV-GLS, LV-GRS and LV-GCS, respectively), left ventricular systolic twist (LV-twist) and right ventricular free wall longitudinal strain (RV-FWLS) were analyzed just before the procedure. We also measured biomarkers at the same moment. Results: Among the included 60 patients, 17 (28%) had severe ACR (grade ≥ 2R), and 43 (72%) had no significant ACR (grade 0 – 1R). The absolute values of LV-GLS, LV-twist and RV-FWLS were lower in transplant patients with ACR degree ≥ 2 R than in those without ACR (12.5% ± 2.9% vs 14.8% ± 2.3%, p=0.002; 13.9° ± 4.8° vs 17.1° ± 3.2°, p=0.048; 21.4%± 3.2% vs 16.6% ± 2.9%, pConclusion: Heart transplant patients have altered left ventricular dynamics compared with control individuals. The combination of troponin with strain parameters had higher accuracy for the detection of ACR than the isolated variables and this association might select patients with a higher risk for ACR who will benefit from an EMB procedure in the first year after heart transplantation.


  • Open Access

    Right ventricular free wall longitudinal strain as determined by speckle tracking echocardiography is a noninvasive predictor of acute cellular rejection in adult heart transplantation

    by Cecília Beatriz Bittencourt Viana Cruz, Ludhmila A. Hajjar, Fernando Bacal, Marco S. Lofrano-Alves, Márcio S.M. Lima, Maria C. Abduch, Marcelo L.C. Viera, Hsu P. Chiang, Juliana B. C. Salviano, Isabela Bispo Santos da Silva Costa, et al.

    Background Acute cellular rejection (ACR) is a major complication after heart transplantation. Endomyocardial biopsy (EMB) remains the gold standard for its diagnosis, but with concerning complications. We evaluated the usefulness of speckle tracking echocardiography (STE) and the biomarkers for detecting ACR after heart transplantation. Methods We prospectively studied 60 transplant patients with normal left and right ventricular systolic function who underwent EMB for surveillance sixth months after transplantation. Sixty age- and sex-matched healthy individuals constituted the control group. Conventional echocardiographic parameters left ventricular global longitudinal, radial and circumferential strain (LV-GLS, LV-GRS and LV-GCS, respectively), left ventricular systolic twist (LV-twist) and right ventricular free wall longitudinal strain (RV-FWLS) were analyzed just before procedure. We also measured biomarkers at the same moment. Results Of 60 patients included, 17 (28%) had severe ACR (grade ≥ 2R) and 43 (72%) had no significant ACR (grade 0–1R). Absolute values of LV-GLS, LV-twist and RV-FWLS were lower in transplant patients with ACR degree ≥ 2 R compared with those without ACR (12.5% ± 2.9 vs 14.8% ± 2.3, p = 0.002 ; 13.9° ± 4.8 vs 17.1° ± 3.2, p = 0.048; 21.4%± 3.2 vs 16.6% ± 2.9, p < 0.001; respectively), while no differences were observed in both LV-GRS or LV-GCS. All these parameters were lower in transplant group without ACR than in non-transplant controls, except for LV-twist. Cardiac troponin I levels were significantly higher in patients with significant ACR than in patients without significant ACR [0.19 (0.09–1.31) vs. 0.05 (0.01–0.18), p = 0.007]. In multivariate analysis, RV-FWLS was the only independent predictor of ACR (odds ratio = 0.57; 95% CI = 0.40–0.81; p = 0.02). RV-FWLS < 18.0% had an accuracy of 85% to predict ACR. Conclusion Heart transplant patients have altered left ventricular dynamics compared with non-transplant individuals. RV-FWLS was the only independent predictor of ACR after heart transplantation and should be considered a valuable noninvasive screening parameter for its detection.